Join
Live feed
·
PRReleasevia Quantisnow
Akari Therapeutics plc logo

Akari Therapeutics Discusses Breakthrough Potential of AKTX-101 and Novel Spliceosome-Modulating ADC Platform in Virtual Investor "What This Means" Segment Following ASCO Abstract Acceptance

ByQuantisnow·Wall Street's wire, on your screen.
AKTX· Akari Therapeutics plc
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track AKTX (Akari Therapeutics plc) and more on Quantisnow.